Spero Therapeutics, Inc.
SPRO · XNASCIK 1701108fmd_0FYRTHTNVEFZ5HQ2KJZXNCDK2DManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Sep 30, 2026, 44 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 2 | 4 | 18 | 9 | 18 | 54 | 104 | 48 | 67 |
| Realized investment gains (losses) | – | – | – | 0 | – | – | – | – | – | – |
| Research and development | 26 | 33 | 34 | 66 | 67 | 65 | 48 | 51 | 97 | 38 |
| Total operating expenses | 34 | 44 | 47 | 81 | 88 | 106 | 96 | 82 | 121 | 60 |
| Operating income | (33) | (42) | (43) | (63) | (79) | (88) | (42) | 21 | (73) | 6 |
| Interest and investment income | – | – | 1 | 1 | 0 | 0 | 1 | 4 | 5 | 3 |
| Other non-operating income (expense) | 1 | 2 | 1 | 2 | 1 | (2) | (4) | 4 | 5 | 3 |
| Income before taxes | (33) | (40) | (42) | (61) | (78) | (90) | (46) | 25 | (69) | 9 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 |
| Net income from continuing operations | (33) | (40) | (42) | (61) | (78) | (90) | (46) | 23 | (69) | 9 |
| Net income | (25) | (39) | (42) | (61) | (78) | (90) | (46) | 23 | (69) | 9 |
| Net income to common shareholders | (30) | (46) | (42) | (61) | (79) | (90) | 46 | – | – | – |